Valneva SE — FY2023 Form 20-F
Reporting period: Year ended December 31, 2023; this is an annual report, not a standalone Q4 filing. Valneva is a France-based specialty vaccine developer, manufacturer and commercializer. Financial statements are prepared under IFRS and presented in euros. The audited statements received an unqualified opinion.
Business context and key financial metrics
Valneva markets travel vaccines IXIARO/JESPECT and DUKORAL, distributes third-party vaccines, and is advancing vaccine candidates including chikungunya vaccine IXCHIQ and Pfizer-partnered Lyme candidate VLA15. The FDA approved IXCHIQ in November 2023; U.S. commercial launch began in early 2024.
| Metric (€ millions, except per-share data) | FY2023 | FY2022 |
|---|---|---|
| Revenue | 153.7 | 361.3 |
| Product sales | 144.6 | 114.8 |
| Operating loss | (82.1) | (113.4) |
| Net loss | (101.4) | (143.3) |
| Adjusted EBITDA loss (non-IFRS) | (65.2) | (69.2) |
| Cash used in operating activities | (202.7) | (245.3) |
| Cash and cash equivalents at year-end | 126.1 | 289.4 |
| Borrowings and lease liabilities at year-end | 208.8 | 152.4 |
Commercial product-sales gross margin was 46.0%, compared with 45.5% in 2022. The company reported total assets of €460.1 million and equity of €128.2 million at year-end. Borrowings were €176.8 million and lease liabilities €32.0 million; cash less those balances implies approximately €82.7 million of net debt.
Material changes versus FY2022
- Revenue fell 57%, mainly because 2022 included large, non-recurring COVID-19 agreement revenue. Other revenue declined to €9.1 million from €246.5 million.
- Product sales rose 26% as travel markets recovered: IXIARO sales increased 78% to €73.5 million; DUKORAL rose 72% to €29.8 million; third-party product sales grew 34% to €35.7 million. VLA2001 sales fell to €5.7 million from €29.6 million as the program was wound down.
- Operating expenses fell to €257.3 million from €486.9 million, largely reflecting the prior-year COVID-19 inventory write-downs and other wind-down costs. R&D expense decreased 43% to €59.9 million, while marketing and distribution expense rose to €48.8 million, including IXCHIQ launch preparation.
- Net loss narrowed, but operating cash use remained substantial. Year-end cash fell by €163.4 million from 2022; 2023 financing cash inflows included €81.1 million net proceeds from borrowings.
Outlook, risks and unusual items
- Management said year-end 2023 cash was expected to fund current operating plans for at least 12 months after publication of the financial statements. Separately, Valneva received $103 million gross from selling its IXCHIQ Priority Review Voucher on February 2, 2024; this post-year-end proceeds amount was not included in year-end cash.
- IXCHIQ’s U.S. approval used an accelerated pathway based on an immune-response surrogate. Continued approval is contingent on verification of clinical benefit through two required Phase 4 studies. The CDC/ACIP recommendation issued in February 2024 is narrower than the U.S. label, which may constrain demand. Valneva expected regulatory decisions in Europe, Canada and Brazil during 2024.
- VLA15’s Phase 3 trial enrolled 9,437 participants and was expected to conclude by the end of 2025, with Pfizer targeting regulatory submissions in 2026 if results are positive. Pfizer leads late-stage development and commercialization; Valneva funds 40% of shared development costs and bears execution and funding risk. A third-party site’s GCP violations led Pfizer to discontinue approximately half of participants then enrolled and delayed the planned submission timeline.
- Cash burn, continued losses, high-cost secured debt and covenant compliance remain central risks. The Deerfield/OrbiMed facility carried a 9.95% stated rate (10.09% annualized under its calculation method), was secured by substantially all assets including intellectual property, and had year-end minimum revenue and liquidity covenants of €115 million and €35 million. A March 2024 amendment changed covenant terms, but the filing text provided here does not give the revised thresholds.
- Supply constraints affected IXIARO and DUKORAL in 2022–2023; Valneva also disclosed anticipated early-2024 supply difficulties. IXIARO and IXCHIQ commercial drug substance rely on the Livingston site, and DUKORAL on Solna. Some materials have single-source suppliers. German distribution agreements with Bavarian Nordic end in 2025.
- Unusual accounting items include the substantial 2022 COVID-19-related revenue and inventory write-downs, and 2023 grant and supplier-settlement income. The Pfizer collaboration’s variable revenue recognition and refund liabilities involved significant management judgment and were identified as a critical audit matter. DUKORAL impairment headroom is limited; a 10% revenue reduction was estimated to trigger an additional €6.5 million impairment.
- The company reported that previously identified material weaknesses in internal control were remediated and that controls were effective at December 31, 2023; the auditors also gave an unqualified opinion on internal control. A €5.2 million provision remains for litigation concerning the 2013 Intercell/Vivalis merger.
Most important facts for investors to verify
- Whether the $103 million PRV proceeds were received in full and how management allocates them among R&D, commercialization and liquidity needs.
- The amended Deerfield/OrbiMed covenant thresholds, compliance headroom, repayment schedule and any material restrictions following the March 2024 amendment.
- IXCHIQ launch uptake, access and sales, the commercial impact of the narrower ACIP recommendation, and the timelines and requirements for Phase 4 studies and non-U.S. approvals.
- VLA15 trial progress after the GCP-related site issue, remaining Valneva funding obligations, and Pfizer’s development and submission milestones.
- IXIARO and DUKORAL supply recovery, inventory quality and expiry exposure, and replacement distribution plans in Germany and Switzerland after the Bavarian Nordic agreements end.